The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 17, 2010
Filed:
Dec. 06, 2001
Luis Enrique Fernandez Molina, Havana, CU;
Belinda Sanchez Ramirez, Havana, CU;
Eduardo Raul Suarez Pestana, Havana, CU;
Anabel DE LA Barrera Aira, Havana, CU;
Circe Mesa Pardillo, Havana, CU;
Joel DE Leon Delgado, Havana, CU;
Yildian Diaz Rodriguez, Havana, CU;
Rolando Perez Rodriguez, Havana, CU;
Luis Enrique Fernandez Molina, Havana, CU;
Belinda Sanchez Ramirez, Havana, CU;
Eduardo Raul Suarez Pestana, Havana, CU;
Anabel de la Barrera Aira, Havana, CU;
Circe Mesa Pardillo, Havana, CU;
Joel de Leon Delgado, Havana, CU;
Yildian Diaz Rodriguez, Havana, CU;
Rolando Perez Rodriguez, Havana, CU;
Centro de Immunologia Molecular, Ciudad de la Havana, CU;
Abstract
This invention discloses means for obtaining immunogenic peptides, polypeptides, proteins, and their corresponding nucleic acid sequences, target cells with vaccine interest, or lysates thereof, without making structural changes in said antigens, through their association with Very Small Size Proteoliposomes. The object of the invention is to provide immunogenic compositions containing peptides, polypeptides, proteins, their corresponding DNA sequences, cells or their lysates and Very Small Size Proteoliposomes (VSSP), which are formed by binding the Outer Membrane Protein Complex (OMPC) ofwith gangliosides, by means of hydrophobic links. Additionally, it is stated that these compositions can be formulated alone or in the form of emulsions with the Incomplete Freund's Adjuvant (IFA), and may also be lyophilized. The essence of the invention consists in describing compositions that triggers immunogenicity in low immunogenic antigens, such as growth factor receptors, without imparting structural changes therein. Particularly, this invention refers to preparation of immuno-stimulating compositions capable of generating antigen-specific immune responses, even in immuno-compromised hosts, such as those suffering form cancer or viral or bacterial chronic infections. In said patients, the administration of the vaccine compositions described in this invention has lead to the reestablishment of the functionality of the immune system. Vaccine compositions of this invention can be used to protect or treat infectious, or auto-immune diseases.